Drug Type Proteolysis-targeting chimeras |
Synonyms- |
Target |
Mechanism FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), c-Kit inhibitors(Stem cell growth factor receptor inhibitors), Proteolysis |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H38FN9O6 |
InChIKeyLOZMISVXTOAAHE-UHFFFAOYSA-N |
CAS Registry2732969-67-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Preclinical | CN | 25 Oct 2021 | |
Acute Myeloid Leukemia | Preclinical | CN | 25 Oct 2021 |